We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer; Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology. Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer; Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
Tirzepatide reduced sleep apnea severity by up to nearly two-thirds in adults with obstructive sleep apnea (OSA) and obesity PR Newswire INDIANAPOLIS, April 17, 2024 Tirzepatide achieved a mean...
Lilly Confirms Date and Conference Call for First-Quarter 2024 Financial Results Announcement PR Newswire INDIANAPOLIS, April 16, 2024 INDIANAPOLIS, April 16, 2024 /PRNewswire/ -- Eli Lilly and...
Taiwan Semiconductor Manufacturing Company (NYSE:TSM) – TSMC evacuated some factories and suspended operations after a 7.4 magnitude earthquake hit Taiwan, raising concerns about the global...
More than two-thirds of people with atopic dermatitis and skin of color experienced skin improvement in a first-of-its-kind lebrikizumab study PR Newswire INDIANAPOLIS, March 10, 2024...
U.S. Food and Drug Administration to Convene Advisory Committee Meeting to Discuss the TRAILBLAZER-ALZ 2 Study of Donanemab PR Newswire INDIANAPOLIS, March 8, 2024 INDIANAPOLIS, March 8, 2024...
Lilly's Newest Phase of Get Better Campaign Challenges Misperceptions About Obesity Care PR Newswire INDIANAPOLIS, March 7, 2024 Two new films draw attention to the importance of treating obesity...
Lilly Announces Details of Presentations at 2024 American Association for Cancer Research (AACR) Annual Meeting PR Newswire INDIANAPOLIS, March 5, 2024 INDIANAPOLIS, March 5, 2024 /PRNewswire/...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -22.94 | -3.06033965234 | 749.59 | 754.72 | 718.3 | 2348467 | 734.62392005 | CS |
4 | -53.67 | -6.87794750871 | 780.32 | 793.67 | 718.3 | 2385837 | 755.77020186 | CS |
12 | 79.07 | 12.210074431 | 647.58 | 800.78 | 643.17 | 3050185 | 751.60744719 | CS |
26 | 129.58 | 21.7026479307 | 597.07 | 800.78 | 547.61 | 3082028 | 669.06351772 | CS |
52 | 341.6 | 88.7157512011 | 385.05 | 800.78 | 370.68 | 3046811 | 583.81651137 | CS |
156 | 538.08 | 285.34761627 | 188.57 | 800.78 | 178.5779 | 2993108 | 387.09948658 | CS |
260 | 608.9 | 517.112526539 | 117.75 | 800.78 | 101.36 | 3333694 | 274.61189213 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions